+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study.

      Archives of Iranian medicine

      Antiviral Agents, therapeutic use, Cross-Sectional Studies, Disease Outbreaks, statistics & numerical data, Hemorrhagic Fever, Crimean, drug therapy, epidemiology, virology, Humans, Iran, Ribavirin, Time Factors, Treatment Outcome

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Crimean-Congo hemorrhagic fever was rarely reported from Iran before 1999. In a recent outbreak, the disease has been reported from different provinces of Iran, especially from Sistan and Baluchestan. Ribavirin has been recommended by World Health Organization as a potential therapeutic modality for Crimean-Congo hemorrhagic fever. This study was conducted to determine the clinical outcome and the effect of ribavirin in two groups of patients with Crimean-Congo hemorrhagic fever who were treated at different times. In this cross-sectional study, we evaluated patients with Crimean-Congo hemorrhagic fever who were admitted to Boo-Ali Hospital in Zahedan, a subtropical area in southeastern Iran, at the first three years after beginning of the last outbreak (1999 - 2003) and those who were admitted during 2005 - 2007. First, we found all patients with confirmed Crimean-Congo hemorrhagic fever infection who were treated with oral ribavirin. Then, they were evaluated for recovery and mortality rate. We evaluated 123 patients with confirmed Crimean-Congo hemorrhagic fever infection (91 patients treated between 1999 and 2003, and 32 patients between 2005 and 2007). Among the 91 patients, 73 (80%) survived, and 18 (20%) died of the disease. During 2005 - 2007, among the 32 patients who were treated within three days of onset of the disease, only one (3%) died of the disease. The recovery rate was higher among patients who were admitted during 2005 - 2007 than those hospitalized between 1999 and 2003 (97% vs. 80%). There was a significant (P=0.001) difference in the mortality rate between the two groups. Prompt treatment with oral ribavirin can increase the recovery rate in patients with Crimean-Congo hemorrhagic fever.

          Related collections

          Author and article information



          Comment on this article